Comparison · NCT00095173-3e4d3ef7
Abatacept (Period B) vs Placebo (Period B): Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Abatacept (Period B) vs Placebo (Period B): Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B). Trial comparisons, record NCT00095173-3e4d3ef7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00095173-3e4d3ef7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.2 | 0.118 | 0.318 | wilson | |
| Risk in group 2 | 0.532 | 0.41 | 0.651 | wilson | |
| Risk difference, group 1 minus group 2 | -0.332 | -0.476 | -0.162 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.376 | 0.215 | 0.656 | log | |
| Odds ratio, group 1 over group 2 | 0.22 | 0.0982 | 0.492 | log | |
| Number needed to treat, for one fewer participant with the outcome on Abatacept (Period B) than on Placebo (Period B) | 3.01 | 2.1 | 6.16 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Abatacept (Period B) | Abatacept: 10 milligram per kilogram body weight (mg/kg), limited to a maximum 1000 mg for participants weighing \>100kg; solution infused intravenously (IV), over 90 minutes, once a month for 6 months or until they experienced a flare. | 12 | 60 | OG000 |
| Group 2 | Placebo (Period B) | Placebo: Dextrose 5% in water (D5W) or normal saline (NS) IV infusion, once every 2 weeks for 3 doses, then monthly up to 6 months. Participants were seated or in supine position during infusion. | 33 | 62 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With a Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease With a Flare During Double-Blind Phase (Period B)
- Description
All of the following criteria must be met to be defined as a flare:~* \> 30% worsening in at least 3 of the 6 JRA/JIA core response variables~* \> 30% improvement in not more than 1 of the 6 JRA/JIA core set variables~* ≥ 2 cm of worsening must be present if the Physician or Parent Global Assessment is used to define flare~* worsening in ≥ 2 joints must be present if the number of active joints or joints with limitation of motion is used to define flare based on changes in the surrogate marker, erythrocyte sedimentation rate (ESR)
- Time frame
- Period B (Day 113 to Day 282)
- Population
- All treated participants
Source ClinicalTrials.gov
Trial
- Title
- BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
- NCT number
- NCT00095173
- Phases
- PHASE3
- Conditions
- Juvenile Rheumatoid Arthritis
- Interventions
- Abatacept, Placebo, Abatacept
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2017-01-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00095173?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00095173-3e4d3ef7